Eric K. Rowinsky
Impact in
- Otorhinolaryngology top 0.05%
- Head and Neck Cancer Studies
- Oncology top 0.02%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
Papers in
- Oncology 226
- Cancer Treatment and Pharmacology 108
- Colorectal Cancer Treatments and Studies 50
- HER2/EGFR in Cancer Research 42
- Lung Cancer Research Studies 25
- CAR-T cell therapy research 21
- Neutropenia and Cancer Infections 18
-
- Cancer therapeutics and mechanisms 65
- Co-authors
- Ross C. Donehower (68 shared papers)Hagop Youssoufian (28 shared papers)Manuel Hidalgo (24 shared papers)Roger B. Cohen (4 shared papers)James A. Bonner (4 shared papers)Paul M. Harari (4 shared papers)José Baselga (4 shared papers)J. Giralt (4 shared papers)
- Journals
- Journal of Clinical Oncology (133 papers)Clinical Cancer Research (32 papers)Investigational New Drugs (17 papers)Blood (16 papers)Cancer Chemotherapy and Pharmacology (15 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Eric K. Rowinsky
395 papers receiving 31.2k citations
Eric K. Rowinsky's Hit Papers
Peers
Comparison fields: 5 of 160
- Otorhinolaryngology 2.6k
- Oncology 14.5k
- Pulmonary and Respiratory Medicine 7.0k
- Cancer Research 2.8k
- Genetics 1.6k
Countries citing papers authored by Eric K. Rowinsky
This map shows the geographic impact of Eric K. Rowinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric K. Rowinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric K. Rowinsky more than expected).
Fields of papers citing papers by Eric K. Rowinsky
This network shows the impact of papers produced by Eric K. Rowinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric K. Rowinsky. The network helps show where Eric K. Rowinsky may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric K. Rowinsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 396 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2006 | 3729 |
| 2 | Paclitaxel (Taxol) Hit paper breakdown → | 1995 | 1565 |
| 3 | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Hit paper breakdown → | 2009 | 1384 |
| 4 | Taxol: A Novel Investigational Antimicrotubule Agent Hit paper breakdown → | 1990 | 895 |
| 5 | Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Hit paper breakdown → | 2004 | 893 |
| 6 | Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Hit paper breakdown → | 2001 | 831 |
| 7 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 794 |
| 8 | ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 646 |
| 9 | THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS Hit paper breakdown → | 1997 | 620 |
| 10 | The Current Status of Camptothecin Analogues as Antitumor Agents Hit paper breakdown → | 1993 | 542 |
| 11 | Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) Hit paper breakdown → | 2003 | 525 |
| 12 | 2000 | 493 | |
| 13 | Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial Hit paper breakdown → | 2000 | 479 |
| 14 | 2010 | 441 | |
| 15 | 2006 | 419 | |
| 16 | 1999 | 414 | |
| 17 | 1991 | 365 | |
| 18 | Taxol: the first of the taxanes, an important new class of antitumor agents. | 1992 | 327 |
| 19 | Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. | 1988 | 320 |
| 20 | 1992 | 302 |
About Eric K. Rowinsky
Eric K. Rowinsky is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Immunology, having authored 396 papers that have together received 32.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (108 papers), Cancer therapeutics and mechanisms (65 papers), Colorectal Cancer Treatments and Studies (50 papers), HER2/EGFR in Cancer Research (42 papers), Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (25 papers), CAR-T cell therapy research (21 papers) and Neutropenia and Cancer Infections (18 papers). The work is most often cited by research in Otorhinolaryngology (2.6k citations), Oncology (14.5k citations), Pulmonary and Respiratory Medicine (7.0k citations), Cancer Research (2.8k citations) and Genetics (1.6k citations). Eric K. Rowinsky has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Ross C. Donehower, Hagop Youssoufian, Manuel Hidalgo, Roger B. Cohen, James A. Bonner, Paul M. Harari, José Baselga, J. Giralt, David Raben and Ranjan Sur. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Investigational New Drugs, Blood and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.